Faster-acting insulin aspart improved postprandial glucose (PPG) control in type 1 and type 2 diabetes
New Orleans, US, 13 June 2016 - New phase 3a findings showed that faster-acting insulin aspart demonstrated a statistically significant reduction in HbA1c in type 1 diabetes, compared with NovoRapid® (insulin aspart)1, a comparable HbA1c reduction in type 2 diabetes versus NovoRapid®2 and improved post-meal or postprandial glucose (PPG) control in type 1 and type 2 diabetes1,2. Results from the onset 1 and onset 2 treat-to-target trials comparing faster-acting insulin aspart with NovoRapid® were presented at the 76th annual Scientific Sessions of the American Diabetes Association (ADA) in New Orleans, US.
Read the full release including references
Further information
| Media: | ||
| Katrine Sperling | +45 4442 6718 | krsp@novonordisk.com |
| Åsa Josefsson | +45 3079 7708 | aajf@novonordisk.com |
| Investors: | ||
| Peter Hugreffe Ankersen | +45 3075 9085 | phak@novonordisk.com |
| Melanie Raouzeos | +45 3075 3479 | mrz@novonordisk.com |
| Kasper Veje (US) | +1 609 235 8567 | kpvj@novonordisk.com |
Attachment
